Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LGBTQ Loyalty Holdings, Inc.LFAP · Entity 132434 | 10% owner | June 04, 2019 | June 26, 2019 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Chief Commercial Officer | January 03, 2022 | January 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LGBTQ Loyalty Holdings, Inc.
Report date June 04, 2019 · Filed June 26, 2019
Jointly reported with Maxim Partners LLC, MJR Holdings LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-06-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-06-04 · Other · Disposed 120,959,996 · Balance 0 F2: Maxim Partners LLC entered into a securities exchange agreement with LGBTQ Loyalty Holdings, Inc. pursuant to which the Maxim Partners LLC exchanged 129,558,574 shares of Common Stock for 129,559 shares (the "Exchange Shares") of our Series C Preferred Stock (the "Share Exchange"). At the request of the Maxim Partners LLC, the Exchange Shares were transferred and issued to Pride Partners LLC, an affiliate of Maxim Partners LLC. F1: All of the securities reported herein were owned directly by Maxim Partners LLC ("Maxim Partners") and 79% of the securities reported herein, or 95,558,397 shares, were indirectly owned by MJR Holdings LLC ("MJR") which owns 79% of the membership interests in Maxim Partners and Michael Rabinowitz is the principal of MJR. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the securities reported herein were owned directly by Maxim Partners LLC ("Maxim Partners") and 79% of the securities reported herein, or 95,558,397 shares, were indirectly owned by MJR Holdings LLC ("MJR") which owns 79% of the membership interests in Maxim Partners and Michael Rabinowitz is the principal of MJR.
F2: Maxim Partners LLC entered into a securities exchange agreement with LGBTQ Loyalty Holdings, Inc. pursuant to which the Maxim Partners LLC exchanged 129,558,574 shares of Common Stock for 129,559 shares (the "Exchange Shares") of our Series C Preferred Stock (the "Share Exchange"). At the request of the Maxim Partners LLC, the Exchange Shares were transferred and issued to Pride Partners LLC, an affiliate of Maxim Partners LLC.
ORAMED PHARMACEUTICALS INC.
Report date January 03, 2022 · Filed January 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,468 |
Reported balance
After 2022-01-03 transaction · row 1
1 source rowRow 1 · 2022-01-03 · Grant · Acquired 19,000 · Balance 109,468 F1: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 4,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-03 | Direct | 32,000 |
Reported balance
After 2022-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-03 · Grant · Acquired 32,000 · Balance 32,000 F2: The Stock Option will vest in 4 installments as follows: 8,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 4,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
F2: The Stock Option will vest in 4 installments as follows: 8,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 6, 2022 01:38 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001213900-22-000814 · ownership.xml · derivative · entry 2 Rabinowitz Michael · CIK 0001767090 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2032-01-03 F2 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 8,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:38 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-000814 · ownership.xml · nonDerivative · entry 1 Rabinowitz Michael · CIK 0001767090 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,468 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 4,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 02:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 9,532 | $12.98 | $123,725.36 |
DisclosureSEC source: 0001213900-21-068230 · ownership.xml · nonDerivative · entry 1 Rabinowitz Michael · CIK 0001767090 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,468 F1 · kind: Payment of tax liability by withholding securities incident to the vesting of the issued security. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 20:01 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $15.10 | $0.00 |
DisclosureSEC source: 0001213900-21-040761 · ownership.xml · derivative · entry 2 Rabinowitz Michael · CIK 0001767090 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-08-04 F3 · derivative.exercise_date: The Stock Options will vest in five installments as follows: 12,500 shall vest on December 31, 2021, 25,000 shall vest on each of December 31, 2022, December 31, 2023 and December 31, 2024, and 12,500 shall vest on August 4, 2025. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 20:01 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-040761 · ownership.xml · nonDerivative · entry 1 Rabinowitz Michael · CIK 0001767090 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · security: Represents common stock underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · date: The RSUs will vest as follows: 33,333 shall vest if the closing price per share of the Issuer's common stock will be $15 for at least 20 days, 33,333 shall vest if the closing price per share of the Issuer's common stock will be $25 for at least 20 days, and 33,334 shall vest if the Issuer consummates an arm's length licensing or other strategic transaction, that includes its phase 3 oral insulin product, for no less than $50,000,000 in upfront cash (including proceeds from any upfront stock equity purchase). Read SEC document |
| June 04, 2019 Filed Jun 26, 2019 14:10 UTC | LGBTQ Loyalty Holdings, Inc. LFAP · Entity 132434 | OtherCommon Stock | 120,959,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-011499 · ownership.xml · nonDerivative · entry 1 Maxim Partners LLC · CIK 0001503205 · 10% owner MJR Holdings LLC · CIK 0001503206 · 10% owner Rabinowitz Michael · CIK 0001767090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Maxim Partners LLC entered into a securities exchange agreement with LGBTQ Loyalty Holdings, Inc. pursuant to which the Maxim Partners LLC exchanged 129,558,574 shares of Common Stock for 129,559 shares (the "Exchange Shares") of our Series C Preferred Stock (the "Share Exchange"). At the request of the Maxim Partners LLC, the Exchange Shares were transferred and issued to Pride Partners LLC, an affiliate of Maxim Partners LLC. F1 · shares: All of the securities reported herein were owned directly by Maxim Partners LLC ("Maxim Partners") and 79% of the securities reported herein, or 95,558,397 shares, were indirectly owned by MJR Holdings LLC ("MJR") which owns 79% of the membership interests in Maxim Partners and Michael Rabinowitz is the principal of MJR. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.